Heart failure is a complex clinical syndrome, whose signs and symptoms are caused by
functional or structural impairment of ventricular filling or ejection of blood. Due to the …

Cancer and cardiovascular disease account for nearly half of all deaths in the US. The
majority of cancer therapies are known to cause potential cardiac toxicity in some form …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

While anti‐cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and
targeted therapy, are constantly advancing, cardiovascular toxicity has become a major …

Because of the rapid growth of cardio-oncology (CO) and the need to provide health care
professionals with clinical practice guidance, there have been a variety of “white papers” …

Cardio-oncology is a new field of interest in cardiology that focuses on the detection,
monitoring, and treatment of cardiovascular disease occurring as a side effect of …

Over the past decade, evolving cancer treatments have resulted in improved overall survival.
It is estimated that there are approximately 15 million cancer survivors in the United States …

Abstract During the 'Heart Failure and World Congress on Acute Heart Failure 2018', many
sessions and lectures focused on cardio‐oncology. This important field of research is …

One specific aim of CO is to render cancer patients fit to receive the best available
anticancer therapy without any compromises or interruptions because of CV problems. 1 …

Background Cardiotoxicity resulting in heart failure (HF) is among the most dreaded
complications of cancer therapy and can significantly impact morbidity and mortality …